Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: Further involvement of mevalonate-pathway blockade for incadronate

Japanese Journal of Pharmacology

Volumn 86, Issue 1, 2001, Pages 86-96

  Fujita, T ^a   Izumo, N ^a   Fukuyama, R ^a   Meguro, T ^a   Yasutomi, C ^a   Nakamuta, H ^a   Koida, M ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Extracellular signal regulated kinase; Ras; Runx2 Cbfa1; Statin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BISPHOSPHONIC ACID DERIVATIVE; COMPACTIN; DRUG METABOLITE; ETIDRONIC ACID; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE TRIPHOSPHATASE; INCADRONIC ACID; LUCIFERASE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSTEOCALCIN; PD 98069; RAS PROTEIN; STATIN; TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; FEMALE; GENE EXPRESSION; IN VIVO STUDY; INTRACELLULAR MEMBRANE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSTEOBLAST; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; TIBIA;

EID: 0034983172     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.86.86     Document Type: Article

References (42)

1. The pharmacology of bisphosphonates and new insights into their mechanisms of action
2. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
4. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
5. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
6. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo
7. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
8. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
9. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
10. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro
11. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry
12. Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionization mass spectrometry
13. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates drugs is dependent on cellular uptake
14. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
15. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
16. Randomised trials of effect of alendronate on risk of fracture in women with existing vertebral fractures
17. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
18. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: Effect of number and spinal location of fractures
19. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
20. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass
21. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
22. Alendronate modulates osteogenesis of human osteoblastic cells in vitro
23. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo
24. Prevention of osteocyte and osteoblast apoptosis by bisphophonates and calcitonin
25. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential
26. Stimulation of bone formation in vitro and in rodents by statins
27. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblast
28. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
29. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1
30. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
31. Large clostridial cytotoxins - A family of glycosyltransferases modifying small GTP-binding proteins
32. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
33. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
34. Bone anabolic effects of PTH (1-34) and salmon calcitonin in ovariectomy- and ovariectomy-steroid-induced osteopenic rats: A histomorphometric and biochemical study
35. Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats
36. Cloning and characterization of the mouse pituitary adenylate cyclase-activating polypeptide (PACAP) gene
37. T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway
38. Phosphate is a specific signal for induction of osteopontin gene expression
39. Phosphate provides an extracellular signal that drives nuclear export of Runx/Cbfa1 in bone cells
40. Transport of proteins and RNAs in and out of the nucleus
41. Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro
42. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between runx2 and smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12